Novo Nordisk rebrands as Novo in its obesity fight with Eli Lilly
Novo held 38.8% of the obesity market in the second quarter against Lilly's 60.9%, and its shares are down about 15% this year.
Intelligence
The parties
Activity
Novo held 38.8% of the obesity market in the second quarter against Lilly's 60.9%, and its shares are down about 15% this year.
Intelligence
Activity